BNR
Burning Rock Biotech Limited
NASDAQ · CNHealthcareMedical - Diagnostics & Research
$10.07+1.00%
Price as of Jul 20, 2026
BNR financials
Burning Rock Biotech Limited financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $539.6M | $515.8M | $537.4M | $563.2M |
| Cost of revenue | $136.7M | $153.4M | $174.2M | $183.2M |
| Gross profit | $402.9M | $362.4M | $363.2M | $380.0M |
| Operating expenses | $457.8M | $720.0M | $1.0B | $1.4B |
| Operating income | -$54.8M | -$357.6M | -$669.3M | -$980.4M |
| Net income | -$55.3M | -$346.6M | -$653.7M | -$971.2M |
| EBITDA | -$32.0M | -$270.2M | -$517.9M | -$845.2M |
| Basic EPS | $-49.60 | $-33.67 | $-63.84 | $-93.47 |
| Diluted EPS | $-49.60 | $-33.67 | $-63.84 | $-93.47 |
| Balance sheet | ||||
| Cash & equivalents | $481.4M | $519.8M | $615.1M | $905.5M |
| Total assets | $820.9M | $885.3M | $1.0B | $1.6B |
| Total liabilities | $285.3M | $304.5M | $271.6M | $429.1M |
| Stockholders’ equity | $535.6M | $580.8M | $768.4M | $1.2B |
| Total debt | $43.1M | $52.3M | $12.3M | $50.8M |
| Net debt | -$438.2M | -$467.5M | -$602.8M | -$854.7M |
| Cash flow | ||||
| Operating cash flow | -$28.4M | -$92.3M | -$255.8M | -$456.8M |
| Capital expenditure | -$5.2M | -$6.0M | -$9.4M | -$62.0M |
| Free cash flow | -$33.7M | -$98.2M | -$265.2M | -$518.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | -$72.0K | -$7.0M | -$71.8M |